- Details
- Samuel Denmeade, Co-Director of the Johns Hopkins Prostate Cancer Program joins Alicia Morgans in a discussion on Bipolar Androgen Therapy (BAT) for prostate cancer. ADT slows prostate cancer’s progress by shutting off testosterone. Eventually, cancer adapts to this new environment and PSA levels start to rise. The concept of BAT is for men whose prostate cancer has become resistant to standard ho...
|
- Details
- Martin Sjöström discusses his groundbreaking research on liquid biopsy biomarkers in prostate cancer. Dr. Sjöström’s team is developing a platform that uses the epigenetic modification, 5-hydroxymethylcytosine (5hmC), found in cell-free DNA circulating in the blood, to predict a patient's response to therapy and detect treatment resistance earlier. The novel approach provides broader and more comp...
|
- Details
- Alicia Morgans and Emmanuel Antonarakis discuss an ongoing biomarker analysis aimed at identifying a molecular signature predictive of response in the COMBAT study. The COMBAT study is a multi-center, single-arm, open label Phase 2 study in asymptomatic patients with mCRPC who had soft tissue metastases amenable to biopsy, and who progressed on at least one prior novel AR-targeted therapy (and up...
|
- Details
- In this discussion, Neal Shore speaks with Alicia Morgans to discuss their experiences and insights on topics ranging from survivorship to new developments in the treatment of metastatic castration-resistant prostate cancer (mCRPC). Dr. Morgans highlights her work in the EAU session on mCRPC, outlining the significance of PARP inhibitors, the PROpel and MAGNITUDE trials, and the potential role of...
|
- Details
- Alicia Morgans speaks with Oliver Sartor about the SPLASH trial and advances in radioligand therapy. The SPLASH trial involves PSMA I&T Lutetium-177 (renamed PNT2002) for pre-chemo, metastatic CRPC patients, with some differences in dose and schedule compared to PSMA 617. In the lead-in study involving 27 PSMA PET-selected patients, the initial PSA 50 response rate was 40%, and the radiographic re...
|
- Details
- Alicia Morgans speaks with Neal Shore about advancements in treating metastatic castration-resistant prostate cancer (mCRPC). They discuss the implications of the newly approved PSMA-RLT lutetium-617, a radiopharmaceutical, adding it to a list of existing therapies such as taxane therapy, PARP inhibitors, and immunotherapies like sipuleucel-T. Dr. Shore emphasizes that monotherapy is no longer acc...
|
- Details
- Alicia Morgans interviews Karim Fizazi to discuss his presentation on the CYPIDES Phase I-II trial. The trial focuses on ODM-208, a CYP11 inhibitor developed with Orion, aimed at treating men with advanced prostate cancer who have exhausted conventional therapies and exhibit androgen receptor mutations. Dr. Fizazi explains that the compound targets the precursor enzymes for various steroids, there...
|
- Details
- Alicia Morgans speaks with Neal Shore, focusing on the PROpel study which evaluates the efficacy of Olaparib and Abiraterone versus Abiraterone alone in treating first-line metastatic castration-resistant prostate cancer. Dr. Shore expresses excitement over the positive findings, particularly the benefits seen across all patient populations, not just those with HRR mutations. The conversation delv...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss the Annals of Oncology article titled “Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2 trial.” The goal of this publication was to determine the optimal treatment for poor prognosis metastatic castration-resistant prostate cancer (mCRPC) p...
|
- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference, Noel Clarke presents the role of PARP inhibitors for all patients with metastatic castration-resistant prostate cancer (mCRPC). Biographies: Noel Clarke, MBBS, FRCS, ChM, Professor of Urological Oncology, Salford Royal Hospital & The Christie NHS Foundation Trust, Manchester, UK Related Content: APCCC 2022: Debate: PARP Inhibitors for All...
|
